ArticleACS chemical biology2015
Large-scale metabolomics reveals a complex response of Aspergillus nidulans to epigenetic perturbation.
Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 98 citations in OpenAlex.
- Global survey of secondary metabolism inPNAS nexus · 2025Article
- Regulation and induction of fungal secondary metabolites: a comprehensive review.Archives of microbiology · 2025Review
- Stepping out of the dark: how metabolomics shed light on fungal biology.FEMS microbiology reviews · 2025Review
- Fungal Metabolomics: A Comprehensive Approach to Understanding Pathogenesis in Humans and Identifying Potential Therapeutics.Journal of fungi (Basel, Switzerland) · 2025Review
- Multiplexed activity metabolomics for isolation of filipin macrolides from a hypogean actinomycete.The Journal of antibiotics · 2025Article
- Regulation of Histone Acetylation Modification on Biosynthesis of Secondary Metabolites in Fungi.International journal of molecular sciences · 2024Review
- A Close View of the Production of Bioactive Fungal Metabolites Mediated by Chromatin Modifiers.Molecules (Basel, Switzerland) · 2024Review
- Endophytic fungi as a potential source of anti-cancer drug.Archives of microbiology · 2024Review
- Chemical Epigenetic Regulation Secondary Metabolites Derived fromMolecules (Basel, Switzerland) · 2024Article
- Harnessing regulatory networks in Actinobacteria for natural product discovery.Journal of industrial microbiology & biotechnology · 2024Review
- The KdmB-EcoA-RpdA-SntB (KERS) chromatin regulatory complex controls development, secondary metabolism and pathogenicity in Aspergillus flavus.Fungal genetics and biology : FG & B · 2023Article
- Beyond Penicillin: The Potential of Filamentous Fungi for Drug Discovery in the Age of Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2023Review
- Correlative metabologenomics of 110 fungi reveals metabolite-gene cluster pairs.Nature chemical biology · 2023Article
- Review
- Recent Advances in Search of Bioactive Secondary Metabolites from Fungi Triggered by Chemical Epigenetic Modifiers.Journal of fungi (Basel, Switzerland) · 2023Review
- The SWC4 subunit of the SWR1 chromatin remodeling complex is involved in varying virulence ofVirulence · 2022Article
- Application of Metabolomics in Fungal Research.Molecules (Basel, Switzerland) · 2022Review
- The KdmB-EcoA-RpdA-SntB chromatin complex binds regulatory genes and coordinates fungal development with mycotoxin synthesis.Nucleic acids research · 2022Article
- How to Completely Squeeze a Fungus-Advanced Genome Mining Tools for Novel Bioactive Substances.Pharmaceutics · 2022Review
- Post-translational modifications drive secondary metabolite biosynthesis in Aspergillus: a review.Environmental microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The microbial world offers a rich source of bioactive compounds for those able to sift through it. Technologies capable of quantitatively detecting natural products while simultaneously identifying known compounds would expedite the search for new pharmaceutical leads. Prior efforts have targeted histone deacetylases in fungi to globally activate the production of new secondary metabolites, yet no study has directly assessed its effects with minimal bias at the metabolomic level. Using untargeted metabolomics, we monitored changes in >1000 small molecules secreted from the model fungus, Aspergillus nidulans, following genetic or chemical reductions in histone deacetylase activity (HDACi). Through quantitative, differential analyses, we found that nearly equal numbers of compounds were up- and down-regulated by >100 fold. We detected products from both known and unknown biosynthetic pathways and discovered that A. nidulans is capable of producing fellutamides, proteasome inhibitors whose expression was induced by ∼100 fold or greater upon HDACi. This work adds momentum to an "omics"-driven resurgence in natural products research, where direct detection replaces bioactivity as the primary screen for new pharmacophores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.